A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
This study is looking at a new gene therapy called delandistrogene moxeparvovec for boys with Duchenne Muscular Dystrophy (DMD). It's designed to see how safe the treatment is and how well it works. Boys who can walk and those who can't will be included. This is a scientific study where some participants will receive the active treatment and others will receive a placebo, which looks like the real thing but has no active medicine. This helps researchers understand the true effects of the new therapy. Everyone in the study will eventually have the chance to receive the actual gene therapy. The study will last for about two and a half years.
Överblick
Vad handlar denna studie om?
This study is testing a new gene therapy called delandistrogene moxeparvovec. Gene therapy is a cutting-edge type of treatment that aims to correct the root cause of certain genetic conditions. In the case of Duchenne Muscular Dystrophy (DMD), this new therapy is designed to help the body make a missing protein called dystrophin, which is vital for healthy muscle function.
The study involves boys with DMD, including those who are still able to walk and those who are no longer able to. Researchers want to understand if this new therapy can slow down or stop the progression of the disease and improve muscle strength. They also need to make sure the treatment is safe.
It's important to remember that this is a research study, and while the goal is to find better treatments, there are no guarantees about the results. The study follows strict ethical guidelines to protect the participants.
Viktiga punkter
- Tests a new gene therapy (delandistrogene moxeparvovec) for DMD.
- Includes boys who can and cannot walk.
- Compares the therapy to a placebo in the first stage.
- All participants will eventually receive the active therapy.
- The study lasts for about two and a half years.
- Careful health checks and muscle tests will be done throughout.
Vem kan vara berättigad?
To join this study, boys must have been officially diagnosed with Duchenne Muscular Dystrophy (DMD) through medical tests and genetic testing. If they can't walk, they need to meet specific health checks. If they can walk, they need to be between 8 and under 18 years old.
Participants must be able to follow instructions for special muscle tests. They also need to be on a steady dose of steroid medication for at least 12 weeks before starting the study, and this dose shouldn't change much during the study. Boys cannot have certain immune system markers, which will be checked with a blood test. Also, their genetic test results for DMD must show a specific type of change in the DMD gene, but not changes in exon 8 or 9.
Boys cannot have had other gene therapies or experimental treatments for DMD recently. They also can't have other serious medical conditions or abnormal test results that the study doctors think would make participating unsafe. The study doctors will carefully review all these points.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Do you have an official diagnosis of Duchenne Muscular Dystrophy?
- Have you been on a steady dose of steroid medicine for at least 12 weeks?
- If you can walk, are you between 8 and under 18 years old?
- Have you had other gene therapies or experimental DMD treatments recently? (If yes, you might not be eligible.)
- Do you have any other serious health conditions that a doctor might think makes this study unsafe for you?
Vad innebär deltagande?
If you join this study, you will be in it for about two and a half years (128 weeks). In the first part, some participants will receive the active gene therapy, and others will receive a placebo, which looks like the real treatment but contains no medicine. This is given as a drip into a vein. Neither you, your family, nor your doctors will know whether you received the active treatment or the placebo during this first part.
Throughout the study, you will have regular visits to the clinic. These visits will include checks of your health, blood tests, and special tests to measure your muscle strength and movement. Every participant will eventually have the opportunity to receive the active delandistrogene moxeparvovec gene therapy, either at the beginning of the study or later on.
Potentiella risker och fördelar
Platser (46)
- Arkansas Children's HospitalVerifierat postnummerLittle Rock, USA
- Lucile Packard Children's Hospital StanfordVerifierat postnummerPalo Alto, USA
- University of California at Davis Medical CenterVerifierat postnummerSacramento, USA
- Rady Children's Hospital-San DiegoVerifierat postnummerSan Diego, USA
- University of Florida, UF Health Center for Pediatric Neuromuscular and Rare DiseasesVerifierat postnummerGainesville, USA
- Ann & Robert H. Lurie Barnsjukhus i ChicagoVerifierat postnummerChicago, USA
- The Johns Hopkins Hospital, Charlotte R. Bloomberg Children's Center, Pediatric Clinical Research UnitVerifierat postnummerBaltimore, USA
- Boston BarnsjukhusVerifierat postnummerBoston, USA
- Washington University of St. Louis, St. Louis Children's HospitalVerifierat postnummerSt Louis, USA
- University of Rochester, Department of NeurologyVerifierat postnummerRochester, USA
- Lenox Baker Children's Hospital (Duke University)Verifierat postnummerDurham, USA
- Nationwide BarnsjukhusVerifierat postnummerColumbus, USA
Vanliga frågor
What is Duchenne Muscular Dystrophy?
Duchenne Muscular Dystrophy (DMD) is a genetic condition that causes muscles to become weaker over time.
Vad är genterapi?
Gene therapy is a new type of treatment that tries to fix the genetic problem that causes a disease, like DMD.
Vad är en placebo?
A placebo is a dummy treatment that looks exactly like the real medicine but contains no active ingredients. It helps researchers safely compare the new treatment's effects.
Hur länge kommer studien att pågå?
The study will last for about two and a half years, which is roughly 128 weeks.
Will I or my doctor know if I'm getting the real treatment?
In the first part of the study, neither you, your family, nor your doctors will know if you are receiving the real treatment or the placebo. This is called 'double-blind'.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.